SOPHiA GENETICS was founded in 2011 by biologists who had a vision to create a technology that could make a positive and lasting impact on the world, using data for good. We’ve built a revolutionary technology platform, SOPHiA DDM™, that rapidly distills complex data into actionable insights, enabling clinicians, researchers, and biopharma to reshape the way that we diagnose and treat cancer and rare inherited disorders. The AI fueling our platform learns from the complex genomic and multimodal data provided by our community of users to create a collective intelligence over time. By using the power of data and AI, we are expanding access to data-driven medicine and enabling the patients of today to help the patients of tomorrow. Our science is driven by unrelenting passion for our mission to transform patient care by expanding access to data-driven medicine globally. We wouldn’t be able to achieve all that we have – and all that we will – without our people, who are driven by our shared purpose to ensure that every patient worldwide has equitable access to precision medicine. Our virtues are our behaviors we exhibit every day, and our mantra “We Care” is our driving force.
市場タイムラインとシグナルフィードを解放
過去 90 日間に 2,182 件のシグナル。
この企業が各市場へ参入した順序 — 古い順から新しい順へ
Como o Hospital Mário Penna incorporou NGS à rotina para diagnóstico de neoplasias hematológicas?Implementar uma nova tecnologia em laboratório clínico vai muito além da parte técnica — envolve confiança, adaptação e aprendizado contínuo.Neste webinar, a equipe do Hospital Mário Penna abre as portas do seu laboratório para contar como incorporou duas aplicações de NGS à rotina para investigação de neoplasias mieloides e linfoídes, desde a avaliação do desempenho analítico até os primeiros casos ...
A experiência do Hospital Mário Penna na implementação de soluções para investigação de doenças onco-hematológicas
登録してシグナルフィードをすべて表示
SOPHiA GENETICS の海外展開を競合と比較
SOPHiA GENETICS自社バーは比較対象企業間の相対的な規模を示します。
5 項目の指標| 企業 | 市場 | 新規市場 | モメンタム | アクティビティ | 拡大スコア |
|---|---|---|---|---|---|
 SOPHiA GENETICS自社 | 11 | 0 | -54% | 2.2k | 21 |
急拡大中 — 過去90日間で46件の求人を掲載、前期比183%増。 Sales中心で、スイスに集中。
Boston, MA · 一昨日
Senior Software Engineer
Singapore · 5日前
Director, Subject Matter Expert - APAC
Colombia · 先週
Associate Director / Sr Manager, BioPharma Business Development (West / Central)
スタック全体で50件の技術を検出。
226市場で32件のアクティブなキャンペーン。
終了
終了
終了過去90日間で3件の言及。
SOPHiA GENETICS SAは2026年第2四半期決算説明会に関連してスライド資料を公開し、Seeking Alphaが議事録を提供しています。
SOPHiA Geneticsは2026年第2四半期決算を発表。売上高は2,330万ドルで前年比27.2%増、予想を上回った。GAAPベースEPSはマイナス0.30ドルで予想を0.08ドル下回った。粗利益率は報告ベース64.6%、調整後72.1%に低下。
SOPHiA GENETICSは、アストラゼネカと複数年にわたる提携を発表し、精密腫瘍学療法のための2つのコンパニオン診断を開発・展開し、分散型臨床試験アッセイを世界的に推進します。
認証済みメールと直通電話を解放
無料 · カード不要
SOPHiA GENETICS の事業、市場、成長シグナルに関する簡潔な回答。
Pubrio は 200 以上の市場にわたる進出シグナルを一つのライブグラフに束ね、どの企業が新市場に参入しているかをレベニューチームに示し、タイミングを捉えられるようにします。
© 2026 Pubrio. 無断転載を禁じます。
